Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
R42 Group originates from Dr. Ronjon Nag's Family Office, established by an entrepreneur known for his work with companies sold to Motorola, BlackBerry, and Apple. The firm focuses on early-stage investments in AI, biotechnology, and deep science, with a commitment to supporting entrepreneurs from the idea stage to growth. R42 Group operates as both a limited partner in funds and a direct investor in companies.
This firm invests in early-stage ventures across artificial intelligence, biotechnology, and deep science, covering stages from pre-seed to growth equity. R42 Group emphasizes collaboration with entrepreneurs to develop innovative solutions that align with its values. Check sizes and specific investment amounts are not disclosed.
R42 Group's portfolio includes notable technologies such as Small Molecule Drug Discovery Platform, which targets challenging drug discovery, and AI for Drug Integrity, a technology measuring drug integrity during manufacturing. Other investments include AI Prostate Cancer Diagnostics, Innovative Immunotherapies for cancer and infectious diseases, and Machine Learning for Drug Discovery, focusing on undruggable diseases and aging.
Submit your pitch through their form at r42group.com.
R42 Group typically invests as a limited partner in funds and directly in companies, but specific details on leading rounds are not provided.
Information regarding follow-on investments is not specified in the available data.
The size of R42 Group's current fund is not disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.